Age Group
Entrada given go-ahead to test DMD therapy after two-year hold
Entrada, Muscular Dystrophy, Duchenne, DMD, United States Food and Drug Administration, Adult, Exons
Bavarian Nordic’s Vimkunya Approved by FDA as First Chikungunya Vaccine for Ages 12 and Up
Vimkunya, chikungunya vaccine, Bavarian Nordic, FDA approval, virus-like particle vaccine, adolescents, travelers
GSK’s Penmenvy Gains FDA Approval, Joining Pfizer in 5-in-1 Meningococcal Vaccine Market
Penmenvy, GSK, FDA approval, meningococcal vaccine, 5-in-1 vaccine, Pfizer, Penbraya, invasive meningococcal disease (IMD), adolescents and young adults
FDA Urges Enhanced Authority to Combat Pediatric and Neonatal Medical Device Shortages
FDA, Medical Device Shortages, Pediatric Patients, Neonatal Patients, Supply Chain Vulnerabilities, Regulatory Authority
Sanofi and SK Bioscience Enhance Partnership for Next-Generation Pneumococcal Conjugate Vaccines
Sanofi, SK Bioscience, Pneumococcal Conjugate Vaccines (PCVs), Next-Generation Vaccines, Pediatric and Adult Populations, Phase III Testing, PCV21
Moderna’s RSV Vaccines Face Safety Concerns Over Severe Infections in Infants
Moderna, RSV vaccines, safety concerns, severe infections, infants, mRNA vaccines, FDA, advisory committee
CDC Recommends Pneumococcal Vaccination for Adults 50 Years and Older
Pneumococcal vaccination, CDC recommendations, adults 50 and older, pneumococcal disease prevention, winter respiratory season.
Bavarian Nordic’s Mpox Vaccine Demonstrates Equivalent Efficacy in Teens and Adults: NIH Study
Mpox vaccine, Bavarian Nordic, MVA-BN vaccine, Teenagers, Adults, Antibody response, Safety, Efficacy, NIH study
GSK Advances Co-Administration of RSV and Shingles Vaccines with Positive Phase III Data
GSK, RSV vaccine, Shingles vaccine, Arexvy, Shingrix, co-administration, Phase III data, adult immunization
FDA Approves Revolutionary Re-Expandable Stent for Young Children
FDA approval, re-expandable stent, young children, congenital heart disease, minimally invasive procedures